Advanced Enzyme Technologies Limited has announced its financial performance for the year ended March 31, 2026. The company reported a robust consolidated annual revenue of ₹7,457.57 million and a net profit of ₹1,736.08 million. In addition to the financial results, the Board of Directors has recommended a final dividend of ₹1.35 per share for the financial year 2025-26, underscoring the company’s commitment to delivering long-term value to its shareholders.
Annual Financial Performance Highlights
For the financial year ended March 31, 2026, the company achieved consolidated revenue from operations of ₹7,457.57 million, compared to ₹6,369.10 million in the previous year. The consolidated net profit for the year stood at ₹1,736.08 million, reflecting healthy growth from the ₹1,339.74 million recorded in the previous fiscal year. The standalone net profit for the same period was ₹1,318.06 million.
Dividend and Strategic Outlook
The Board of Directors has recommended a final dividend of ₹1.35 per equity share, representing a 67.5% payout on the face value of ₹2 per share. This proposal is subject to approval at the company’s upcoming 37th Annual General Meeting. Furthermore, the company has decided to defer the declaration of an interim dividend, opting to preserve capital to maintain flexibility for potential strategic investments and corporate actions aimed at maximizing shareholder value.
Leadership Updates and Corporate Governance
The Board has approved the re-appointment of Mr. Mukund Madhusudan Kabra as Whole-time Director for a new 5-year term, effective from April 1, 2027. Additionally, Mr. Pradip Bhailal Shah has been appointed as an Additional Director (Independent) for a 5-year term commencing June 12, 2026. The company also announced the re-appointment of M S K A & Associates LLP as statutory auditors for a second five-year term.
Operational Milestones
During the fiscal year, the company increased its paid-up share capital following the allotment of 49,350 equity shares under its Employees Stock Options Scheme 2022. The company also confirmed the incorporation of a new wholly-owned subsidiary, Advanced Nutrazyme Private Limited, which will focus on the sales and distribution of the company’s nutrition and wellness product portfolio.
Source: BSE
